Wood Mark
Form 4
April 23, 2013

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Wood Mark

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP, Human Resources

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/22/2013 (1)	04/22/2013	M		937	A	$ 14.39	24,182	D	
Common Stock	04/22/2013 (1)	04/22/2013	M		833	A	$ 21.51	25,015	D	
Common Stock	04/22/2013 (1)	04/22/2013	M		812	A	$ 26.49	25,827	D	
Common Stock	04/22/2013 (1)	04/22/2013	M		520	A	$ 37.46	26,347	D	
	04/22/2013 (1)	04/22/2013	S		3,102	D		23,245	D	

Common Stock	$ 65.5748 (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) Common Stock	$ 14.39	04/22/2013 (1)	04/22/2013	M			937	11/12/2009 (3)	05/11/2019	Common Stock	937
Stock Option (right to buy) Common Stock	$ 21.51	04/22/2013 (1)	04/22/2013	M			833	11/12/2010 (4)	05/11/2020	Common Stock	833
Stock Option (right to buy)	$ 26.49	04/22/2013 (1)	04/22/2013	M			812	11/12/2011 (5)	05/11/2021	Common Stock	812
Stock Option (right to buy) Common Stock	$ 37.46	04/22/2013 (1)	04/22/2013	M			520	11/08/2012 (6)	05/07/2022	Common Stock	520

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wood Mark C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			VP, Human Resources	

Signatures

/s/ Laura Woodhead, Attorney-in-Fact	04/23/2013
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 plan executed on August 13, 2012.

(2) The price in Column 4 is a weighted average price. The prices actually received ranged from $65.01 to $66.08. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(3) Original option grant vests 6/48th on November 12, 2009 and 1/48th each on the 12th of each month thereafter.

(4) Original option grant vests 6/48th on November 12, 2010 and 1/48th each on the 12th of each month thereafter. Remarks:

(5) Original option grant vests 6/48th on November 12, 2011 and 1/48th each on the 12th of each month thereafter.

(6) Original option grant vests 6/48th on November 8, 2012 and 1/48th each on the 8th of each month thereafter.

(7) Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.